Overview
The DIA Global QPPV Forum is a must-attend conference for anyone involved in pharmacovigilance. With a focus on the most pressing issues facing the industry today, this year's topics include global QPPV challenges, trends requiring QPPV awareness, and the impact of modern technology on the field. In addition, we will continue our popular 'QPPV talks' - quick, inpirational sessions that provide practical insight into real-world cases.
With input from regulators and industry leaders from around the world, this conference promises to provide valuable insights into the most pressing issues facing QPPVs today - and don't forget our 'Hot Topics' session!
So join us at the DIA Global QPPV Forum to network with peers, gain valuable insights, and stay ahead of the curve in the ever-evolving role.
Why should you attend this conference?
I’m excited to meet you all face-to-face in Amsterdam. As always the program is packed with hot topic presentations and flourishing discussions that cover the entire equator of the QPPV planet. You will recognize many of your favorite sessions but will also get the chance to enter new fields of knowledge. Moreover, the agenda offers plenty of space to socialize and exchange thoughts and experiences with old and new colleagues. So make sure your passport is valid, locate your suitcase - and I’ll see you in November. The QPPV Forum is useful, interesting, and fun! – Magnus Ysander – EU & UK QPPV & Head Pharmacovigilance Excellence, AstraZeneca, Sweden
For me, the annual QPPV forum is the place to meet my colleagues in the field that have just joined or that have been in the QPPV role for decades, all sharing experiences and best-practices in that particular role that is at the core of the pharmacovigilance system. Every year, the agenda includes topics on the further globalization of the role, current developments in (guidance for) legislation and is a platform for interaction between regulators and industry. I am thrilled that this year is in a live setting again and am very much looking forward to meet you in person! – Angela Van der Salm – Director Pharmacovigilance, Managing Partner, DADA Consultancy, Netherlands
Free Session! Management of Shortages and the QPPV involvement
This session provides valuable insights and practical solutions shared by industry and regulators as well as clarify the expectations from the MHRA, including the role of the QPPV in this matter.
Featured
Want to learn more about Global Forum for Qualified Persons for Pharmacovigilance (QPPV)? You've come to the right site!
Program Committee
-
Gemma Jimenez Sese Senior Director, Deputy EU QPPV
AstraZeneca, Spain -
Magnus Ysander, MD EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden -
Angela Van Der Salm, PhD, MSc Director PV, Managing partner
DADA Consultancy B.V., Netherlands -
Shahinaz Badr Pharmacovigilance Consultant and PVQA Auditor - EMEA
Pharma Quality Europe, United Arab Emirates -
Vicki Edwards, RPh Vice President, Pharmacovigilance Excellence and International QPPV
Abbvie, United Kingdom -
Maarten Lagendijk, MSc Deputy EU QPPV
MSD, Netherlands -
Elspeth McIntosh, MBA, RN Director
Castle Pharmacovigilance Ltd, United Kingdom -
Katarzyna Swiderek, MPharm, RPh Director, Safety Evaluation Risk Management (SERM)
GlaxoSmithKline, Poland -
Kiernan Trevett, MSc Quality Policy Lead
Genentech, A Member of the Roche Group, United States -
Claire Longman, MSc Expert Pharmacovigilance Inspector
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Willemijn van der Spuij, MSc Executive Director, WorldWide Patient Safety International, Europe
Switzerland
Have an account?